COCHLEAR LTD ADR 1/2/O.N. Total Liabilities

Latest as of June 2025: €874.70 Million EUR ≈ $1.02 Billion USD

COCHLEAR LTD ADR 1/2/O.N. total liabilities. Based on the latest financial reports, COCHLEAR LTD ADR 1/2/O.N. (OC50) has total liabilities worth €874.70 Million EUR (≈ $1.02 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can COCHLEAR LTD ADR 1/2/O.N. fund operations to measure how many days the company can operate on defensive assets alone.

Total Liabilities of COCHLEAR LTD ADR 1/2/O.N. (2022–2025)

Total liabilities of COCHLEAR LTD ADR 1/2/O.N. from 2022 to 2025. This chart illustrates how COCHLEAR LTD ADR 1/2/O.N.'s total liabilities have evolved over time, based on quarterly financial data. See OC50 equity to assets ratio to measure how much of total assets are equity-financed.

COCHLEAR LTD ADR 1/2/O.N. Competitors by Total Liabilities

The table below lists competitors of COCHLEAR LTD ADR 1/2/O.N. ranked by their total liabilities.

Company Country Total Liabilities
Ramelius Resources Ltd
AU:RMS
Australia AU$483.64 Million
Pampa Energia SA
BA:PAMP
Argentina AR$3.71 Billion
Mercury Systems Inc
NASDAQ:MRCY
USA $1.04 Billion
Jiangsu Etern Co Ltd
SHG:600105
China CN¥5.75 Billion
Spirit Aerosystems Holdings Inc
NYSE:SPR
USA $10.62 Billion
Shanghai Electric Power Co Ltd
SHG:600021
China CN¥149.90 Billion
Amentum Holdings Inc.
NYSE:AMTM
USA $6.41 Billion
Sprouts Farmers Market LLC
NASDAQ:SFM
USA $2.83 Billion

Liability Composition Analysis (2022–2025)

This chart breaks down COCHLEAR LTD ADR 1/2/O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see COCHLEAR LTD ADR 1/2/O.N. (OC50) total assets.

Liquidity & Leverage Metrics

COCHLEAR LTD ADR 1/2/O.N. Total Liabilities Ratios Explained

COCHLEAR LTD ADR 1/2/O.N. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.35 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.45 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.31 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how COCHLEAR LTD ADR 1/2/O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for COCHLEAR LTD ADR 1/2/O.N. (2022–2025)

The table below shows the annual total liabilities of COCHLEAR LTD ADR 1/2/O.N. from 2022 to 2025.

Year Total Liabilities Change
2025-06-30 €874.70 Million
≈ $1.02 Billion
-3.31%
2024-06-30 €904.60 Million
≈ $1.06 Billion
+10.33%
2023-06-30 €819.90 Million
≈ $958.55 Million
+5.20%
2022-06-30 €779.40 Million
≈ $911.20 Million
--

About COCHLEAR LTD ADR 1/2/O.N.

F:OC50 Germany Medical Devices
Market Cap
$4.65 Billion
€3.98 Billion EUR
Market Cap Rank
#3614 Global
#669 in Germany
Share Price
€30.40
Change (1 day)
-38.71%
52-Week Range
€30.40 - €89.50
All Time High
€104.15
About

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor… Read more